Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-222-4 | CAS number: 13701-59-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
Description of key information
A study of acute neurotoxicity is available. Neurotoxicity following repeated (sub-chronic) oral dosing was investigated as part of a 90-day rat study and is reported elsewhere.
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Link to relevant study records
- Endpoint:
- neurotoxicity: acute oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 23 January, 1992 - 8 April, 1993
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was carried out under GLP and followed the appropriate guideline.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 81-8 (Neurotoxicity Screening Battery)
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Source: The Charles River Breeding Laboratories, Inc.
- Age at study initiation:You adult, 43 days old
- Weight at study initiation: Males 197 - 276 g, Females 135 - 184 g
- Fasting period before study: None
- Housing: Individually, in general accordance with the NIH Guide for the Care and Use of Laboratory Animals
- Diet (e.g. ad libitum): Purina Certified Rodent Chow #5002 adlibitum
- Water (e.g. ad libitum): municipal water ad libitum
- Acclimation period: 18 days
- Justification for selection: This species and strain is recognized to be appropriate for subchronic toxicity and neurotoxicity studies.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.6 - 23.9 °C
- Humidity (%): 48-78%
- Air changes (per hr): No data
- Photoperiod (hrs dark / hrs light): 12 hours light/dark cycle
IN-LIFE DATES: From: No data To:No data - Route of administration:
- oral: gavage
- Vehicle:
- other: methyl cellulose
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
An appropriate amount of the test material was weighed for each group and transferred to a mortar. The test material was triturated with a small amount of the vehicle until a slurry was formed. This was then transferred to a graduated cylinder and a sufficient amount of vehicle was added to attain an appropriate volume for mixing. The suspension was mixed on a mixer for approximately 5 minutes to reduce any large particles.
A magnetic stir bar was added and the mixture was stirred continuously throughout the sampling and dosing procedures. Dosing preparations were dispensed on a daily basis for dose administration. Dosing preparations were prepared twice during the study period and were stored at room temperature.
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data
- Concentration in vehicle: Each litre of vehicle was prepared by heating 1000 ml of deionised water to approximately 70 °C and gradually adding 5.0 g of the control material powder. The mixture was stirred until clear. The vehicle was prepared prior to study initiation and stored refrigerated between periods of use.
- Amount of vehicle (if gavage): Dosage volume 5 ml/kg
- Lot/batch no. (if required): 50H0209
- Purity: 0.5% aquous methyl cellulose - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analytical tests: Homogeneity , stability (14 day) and test article concentration analyses were conducted on Busan 11-M1 preparations
Strata sampled: the top, middle and bottom of the Busan 11-M1 preparations were sampled for homogeneity, the middle of a preparation was sample for stability and/or concentration.
Samples size: 10 ml
Sampling schedule: Samples were collected prior to study initiation (homogeneity and stability analyses) and from the preparation used for dosing (concentration analyses).
Performing laboratory: EPL BioAnalytical Services, Inc. - Duration of treatment / exposure:
- - Duration of observation period following administration: 14 days
- Frequency of treatment:
- Once
- Remarks:
- Doses / Concentrations:
25, 50, 100, 200 mg/kg bw
Basis:
actual ingested - No. of animals per sex per dose:
- 12 rats/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on the results of a preliminary range-finding study
- Rationale for animal assignment (if not random): computer randomisation procedure - Observations and clinical examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
- Cage side observations included: mortality and moribundity
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: recorded individually pre-study and on study days 0, 7 and 14
OPHTHALMOSCOPIC EXAMINATION: No - Specific biochemical examinations:
- NEUROPATHY TARGET ESTERASE (NTE) ACTIVITY: No
CHOLINESTERASE ACTIVITY: No - Neurobehavioural examinations performed and frequency:
- FUNCTIONAL OBSERVATIONAL BATTERY: Yes
- Parameters checked:
Home cage observations included posture, convulsions/tremors, faeces consistency, biting and palpebral (eyelid) closure.
Handling observations included ease of removal from cage, ease of handling animal in hand, lacrimation/chromodacryorrhea, salivation, piloerection, fur appearance, palpebral closure, respiratory rate/character, red/crusty deposits, mucous membranes/eye/skin colour, eye prominence and muscle tone.
Open field observations included mobility, gait, rearing, arousal, convulsions/tremors, urination/defecation, grooming, gait score, bizarre/stereotypic behaviour, backing, time to first step.
Sensory observations included approach response, touch response, startle response, tail pinch response, pupil response, eye blink response, forelimb extension, hind limb extension, air righting reflex and olfactory orientation.
Neuromuscular observations included hind limb extensor strength, grip strength-hind and forelimb, hand limb food splay and rotarod performance.
Physiological observations included catalepsy, bodyweight and body temperature.
- Description of procedures: Detailed description available in Appendix D to report
- Minimization of bias: No data
- Same technicians used throughout testing: No data
- Technicians were blind to treatment status of animals: No data
- Site of testing: sound-proofed room equipped with a white noise generator, except home cage observations which were performed in the animal room
- Time schedule for examinations: 4 hours after dosage administration and on study days 7 and 14
- Environmental conditions: sound-proofed room equipped with a white noise generator, except home cage observations which were performed in the animal room
- Noise level:sound-proofed room equipped with a white noise generator, except home cage observations which were performed in the animal room
- Other: No further data
- Scoring criteria (if any): available in Appendix D to report
- Duration of observation period for open field observations: 2 minutes
- Description of equipment where required: No further data
LOCOMOTOR ACTIVITY: Yes
- Replicates used: All animals
- Type of equipment used: Digiscan ‘Micro’ Animal Activity System. Data for ambulatory and total motor activity were tabulated. Total motor activity was defined as a combination of fine motor skills including grooming; interruption of one or two adjacent photobeams and ambulatory motor activity the interruption of three or more consecutive photobeams.
- Length of session, number and length of subsessions: recorded after the completion of the FOB. Data were collected in one minute epochs and the test session duration was 41 minutes.
- Total activity: was defined as a combination of fine motor skills including grooming; interruption of one or two adjacent photobeams and ambulatory motor activity the interruption of three or more consecutive photobeams.
- Ambulatory activity: the interruption of three or more consecutive photobeams.
AUDITORY STARTLE REFLEX HABITUATION: No
LEARNING AND MEMORY TESTING: No - Sacrifice and (histo)pathology:
- - Time point of sacrifice: Day 14
- Number of animals sacrificed: All
- Parameters measured:
- Brain weight: yes excluding olfactory bulbs
- Length and width of brain: yes
- Other: Any observable gross changes, abnormal coloration or lesions of the brain and spinal cord were recorded
- Procedures for perfusion: in situ
- Number of animals perfused: All
- Tissues evaluated: The central and peripheral tissues. Central nervous system tissues: brain (forebrain, centre of cerebrum, midbrain, cerebellum and pons, and the medulla oblongata), spinal cord (at cervical swellings C3-C8 and at lumbar swellings T13-L4), gasserian ganglion/trigeminal nerves, lumbar dorsal root ganglion at T13-L4, lumbar dorsal root fibres at T13-L4, lumbar ventral root fibres at T13-L4, lumbar dorsal root ganglion at C3-C8, lumbar dorsal root fibres at C3-C8, lumbar ventral root fibres at C3-C8, optic nerves, eyes.
Peripheral nervous system tissues: Sciatic nerve (mid-thigh region and at sciatic notch), sural nerve, tibial nerve, peroneal nerve, forelimbs.
- Type of staining:hematoxylin and eosin
- Methodology of preparation of sections: embedded, sectioned and the stained
- Thickness: No data
- Embedding media: plastic or paraffin
- Number of sections: No data
- Number of animals evaulated from each sex and treatment group: 5 animal/sex in the control and 200 mg/kg group. The Sciatic nerve (mid-thigh region and at sciatic notch) and the lumbar dorsal root fibres at T13-L4 were also examined from 5 females each in the 25, 50 and 100 mg/kg groups. - Other examinations:
- No further data
- Positive control:
- No further data
- Statistics:
- Statistical tests for body weight, histopathological and brain data were performed by a Digital MicroVAX 3400 computer with appropriate programming. All analyses were two-tailed for significance levels of 5% and 1%. Each mean was presented with the standard deviation and the number of animals used to calculate the mean. Body weights, body weight changes, brain weights and brain dimensions were analyzed by a one-way ANOVA. If significant differences were indicate, Dunnett’s test was used to compare the control and treat groups. Histopathological findings in the treated groups were compared to the control group data by the one-tailed Kolmogorov-Smirnov test.
All statistical tests for the FOB and locomotor activity data were performed using SAS/STAT statistical software. Each mean was presented with the standard deviation and the number of animals used to calculate the mean. Contiguous FOB data were analyzed using a two-way repeated measures ANOVA. If significant treatment or treatment-time interactions occurred, a one-way ANOVA was conducted at each point. If significant treatment effects were observed at a time point, Dunnett’s multiple T-test was conducted to determine significant treatment differences from the control group (p<0.05). FOB parameters yielding scalar or descriptive data were analyzed using the repeated measures SAS CATMOD procedure. If significant treatment or treatment-time interactions occurred, Fisher’s Exact test or Dunnett’s test were conducted to determine significant treatment differences from the control group. These tests were performed by a Digital MicroVAX 3400 computer with appropriate programming. - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Other effects:
- not examined
- Details on results:
- NEUROBEHAVIOUR
No remarkable differences between animals receiving the test substance and the control animals in locomotor activity.
Differences were found between control animals and males receiving 100 and 200 mg/kg and females receiving 200 mg/kg test substance when the FOB was performed. Specifically, a slight impairment of gait was noted on study day 0, four hours after treatment during the open field testing. The only other possible treatment-related effect was the impairment of hind limb extension for two males in the 200 mg/kg group during the sensory observations on day 0. These effects were transient in nature. No signs of toxicity were apparent on study days 7 and 14. No remarkable differences between the treated and control animals were apparent during the home cage, handling, neuromuscular and physiological observations during pre-test evaluations or on study days 0, 7 and 14. - Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Changes in gait at higher dose levels
- Remarks on result:
- other:
- Conclusions:
- Based on the results of this study, the NOAEL for acute neurotoxicity was considered to be 50 mg/kg.
- Executive summary:
In an acute neurotoxicity study performed by Lamb (1993) groups of 12 rats/sex/dose were dosed with 25, 50, 100, 200 mg/kg Busan 11-M1 by oral gavage. The animals were then observed for mortality and clinical effects, body weight and neurobehavioral parameters, until day 14 at which point they were sacrificed and gross necropsy and neuropathology examinations was performed. There were no mortalities. No effects attributable to treatment were observed in regards to clinical signs, body weight, gross necropsy and neuropathology examinations. There were some neurobehavioral differences that were attributable to treatment found in the 100 and 200 mg/kg dose groups. Based on the results of this study, the NOAEL for acute neurotoxicity was considered to be 50 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 50 mg/kg bw/day
- Species:
- rat
- Quality of whole database:
- A guideline-complinat acute neurotoxicity study is avaialble
Effect on neurotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In an acute neurotoxicity study performed by Lamb (1993) groups of 12 rats/sex/dose were dosed with 25, 50, 100, 200 mg/kg Busan 11-M1 by oral gavage. The animals were then observed for mortality and clinical effects, body weight and neurobehavioral parameters, until day 14 at which point they were sacrificed and gross necropsy and neuropathology examinations was performed. There were no mortalities. No effects attributable to treatment were observed in regards to clinical signs, body weight, gross necropsy and neuropathology examinations. There were some neurobehavioral differences that were attributable to treatment found in the 100 and 200 mg/kg dose groups. Based on the results of this study, the NOAEL for acute neurotoxicity was considered to be 50 mg/kg.
Justification for selection of effect on neurotoxicity via oral route endpoint:
Only one study available
Justification for classification or non-classification
The findings of this study do not trigger classification according to the CLP Regulation
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.